Cargando…

O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

Detalles Bibliográficos
Autores principales:	M., TELEN, R., BROWN, R., HAGAR, M., IDOWU, I., OSUNKWO, T., KALFA, F., KUYPERS, J., GEIB, P., SCHROEDER, E., WU, P., KELLY, S., SARAF
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426851/ http://dx.doi.org/10.1097/01.HS9.0000872820.66998.56

Ejemplares similares

P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH
por: Saraf, S., et al.
Publicado: (2022)

S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
por: Telen, M, et al.
Publicado: (2022)

S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: T., COATES, et al.
Publicado: (2022)

PB2232: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE
por: Lal, A., et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial
por: Forsyth, Sanjeev, et al.
Publicado: (2022)

S131: REGIONAL ASSESSMENT OF THE EXPERIENCES OF HEALTHCARE PROFESSIONALS (HCPS) TREATING PATIENTS WITH SICKLE CELL DISEASE (SCD): THE INTERNATIONAL SICKLE CELL WORLD ASSESSMENT SURVEY (SWAY)
por: Osunkwo, I, et al.
Publicado: (2022)

O-11: AUTOMATED QUANTIFICATION OF POCKED RED BLOOD CELLS CORRELATES WITH SPLEEN SIZE IN SICKLE CELL DISEASE
por: A., SISSOKO, et al.
Publicado: (2022)

O-08: NEUROCOGNITIVE IMPAIRMENT IN UGANDAN CHILDREN WITH SICKLE CELL ANEMIA COMPARED TO NON-SICKLE SIBLINGS
por: P., BANGIRANA, et al.
Publicado: (2022)

5559749 A MULTICENTER, RETROSPECTIVE STUDY ON REAL-WORLD EXPERIENCE OF PATIENTS WITH SICKLE CELL DISEASE TREATED WITH VOXELOTOR
por: Andemariam, B., et al.
Publicado: (2023)

Pyridoxamine: another vitamin for sickle cell disease?
por: Telen, Marilyn J.
Publicado: (2020)

Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients
por: Gutierrez, Mario, et al.
Publicado: (2021)

P03.15. Developing a Health Qigong program for children: a 16-week curriculum
por: Wang, C, et al.
Publicado: (2012)

Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management
por: Ballas, Samir K., et al.
Publicado: (2012)

Biomarkers and recent advances in the management and therapy of sickle cell disease
por: Telen, Marilyn J.
Publicado: (2015)

Erratum to “Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management”
por: Ballas, Samir K., et al.
Publicado: (2013)

5612992 SICKLE CELL HEALTH AWARENESS, PERSPECTIVES, AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND IMPACT ON THE QUALITY OF LIFE OF PATIENTS AND CAREGIVERS IN THE UK
por: Inusa, B.P.D., et al.
Publicado: (2023)

OA10.03. Improved activity, participation, and quality of life for individuals with chronic stroke following an 8-week yoga intervention
por: Van Puymbroeck, M, et al.
Publicado: (2012)

Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease
por: Osunkwo, Ifeyinwa, et al.
Publicado: (2020)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

5613081 GAPS IN DATA ON GLOBAL PREVALENCE AND BIRTH PREVALENCE OF SICKLE CELL DISEASE AND SICKLE CELL TRAIT: CALL FOR ACTION TO SCALE UP AND HARMONIZE DATA COLLECTION
por: Colombatti, R., et al.
Publicado: (2023)

S128: CONTINUOUS QUALITY IMPROVEMENT IN PAEDIATRIC SICKLE CELL DISEASE
por: Ahemad, E, et al.
Publicado: (2022)

Sex differences in progression of kidney disease in sickle cell disease
por: Ataga, Kenneth I., et al.
Publicado: (2022)

S110: ACUTE AND CHRONIC PAIN MANAGEMENT IN SICKLE CELL DISEASE: OUTCOMES OF AN ENGLISH NATIONAL AUDIT.
por: Lugthart, S, et al.
Publicado: (2022)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

Mechanistic insights and characterization of cardiomyopathy due to Sickle Cell Disease
por: Patel, Amit R, et al.
Publicado: (2012)

OA05-03. Efficacy study of a T-cell-based DNA vaccine delivered by intradermal electrotransfer in macaques
por: Dereuddre-Bosquet, N, et al.
Publicado: (2009)

OA06-03. Dynamics of CTL epitope escape and reversion in an African subtype C cohort
por: Schaefer, M, et al.
Publicado: (2009)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

5613275 USE OF CONSUMER WEARABLES TO PREDICT PAIN IN PATIENTS WITH SICKLE CELL DISEASE
por: Vuong, C., et al.
Publicado: (2023)

OA03.02. Acupuncture for back pain: predicting attendance at appointments
por: Bishop, F, et al.
Publicado: (2012)

OA03-06 LB. Unique stimulatory properties of myeloid dendritic cells in individuals with "elite" HIV-1 control
por: Huang, J, et al.
Publicado: (2009)

OA03.12. Herbal socks an effective medication against plantar hyperkeratosis
por: Geethadevi, C, et al.
Publicado: (2013)

Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia
por: Wun, Ted, et al.
Publicado: (2014)

S127: CONSORTIUM ON NEWBORN SCREENING IN AFRICA FOR SICKLE CELL DISEASE
por: Nnodu, O, et al.
Publicado: (2022)

OA16.03. Patients seek integrative medicine for preventive approach to health
por: Wolever, R
Publicado: (2012)

O-10: SICKLE CELL HEALTH AWARENESS, PERSPECTIVES AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND UNMET NEEDS AS REPORTED BY PATIENTS AND CAREGIVERS
por: I., ODAME, et al.
Publicado: (2022)

O-01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB-SAHARAN AFRICA: THE REACH EXPERIENCE
por: A., POWER-HAYS, et al.
Publicado: (2022)

Intrapartum Management of Sickle Cell Anemia With Rare Antibody and Minimal Blood Availability
por: Dom, Aaron M., et al.
Publicado: (2020)

S03-06 OA. Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication
por: Hersperger, AR, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ia3i0brdmfquc04d078a8at71j